Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia

ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). However, given that prolonged monotherapy tends to beget resistance, we sought to investigate the means by which resistance to ABT-199...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2016-06, Vol.6 (1), p.27696-27696, Article 27696
Hauptverfasser:	Lin, Kevin H., Winter, Peter S., Xie, Abigail, Roth, Cullen, Martz, Colin A., Stein, Elizabeth M., Anderson, Gray R., Tingley, Jennifer P., Wood, Kris C.
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/1 13/106 13/95 38/47 692/4028/67/1059/2326 692/4028/67/1059/602 692/4028/67/1990/283/1897 Acute myeloid leukemia Antineoplastic Agents - pharmacology Apoptosis Bcl-2 protein Bcl-x protein bcl-X Protein - genetics bcl-X Protein - metabolism Bridged Bicyclo Compounds, Heterocyclic - pharmacology Cell Line, Tumor Chronic exposure Drug dosages Drug resistance Drug Resistance, Neoplasm Drug therapy Experiments Genetic screening Humanities and Social Sciences Humans Leukemia Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - metabolism Mcl-1 protein multidisciplinary Myeloid Cell Leukemia Sequence 1 Protein - genetics Myeloid Cell Leukemia Sequence 1 Protein - metabolism Peptides Science Sulfonamides - pharmacology Tumor cell lines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!